Skip Navigation Links
Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross(TM) Expander System & Retrieval Sheath
Overall Recruitment Status: Active, currently enrolling
 
Official Title
Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross(TM) Expander System & Retrieval Sheath
 
Region Sponsors
California - Northern
Prodeon Medical, Inc
 
Acronym KP IRB No.
45663160
 
Study Type Phase
Prospective Cohort Study with Direct Patient Contact
 
Study Population Description
 
Purpose
To demonstrate the safety and efficacy of the Urocross Expander System/Retrieval Sheath and the procedure to treat patients with symptomatic Benign Prostatic Hyperplasia (BPH).
 
Detailed Description
 
Gender Age Limit
Male & Female
 
Inclusion Criteria
  • Subject has signed an informed consent form (ICF). Men = 45 years. Symptomatic BPH with the following (all must be met): IPSS = 13. Qmax = 12 mL/sec on a voided volume of = 125 mL. PVR < 250 mL. Prostate volume 30-80 cc measured by transrectal ultrasound (TRUS) or magnetic resonance imaging (MRI) within 6 months prior to randomization. Subjects willing to be off their BPH-related medications from time of enrollment and throughout study participation. Note: All subjects on BPH-related medications must start a washout period prior to qualifying questionnaires and uroflowmetry.
 
Exclusion Criteria
  • Subjects who meet ANY of the following exclusion criteria will not participate in the trial: Previous BPH procedure intended to disobstruct the bladder outlet (e.g., prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate). Obstructive protruding (mobile) middle (median) prostatic lobe as confirmed by cystoscopy. High bladder neck as determined by the Investigator. Urethral stricture, meatal stenosis, or bladder neck contraction - either current, or recurrent requiring 2 or more dilatations. Biopsy of the prostate within past 8 weeks. Baseline Prostate Specific Antigen (PSA) level > 10 ng/mL or confirmed or suspected prostate cancer (subjects with a PSA level > 2.5 ng/mL or whose PSA levels fall outside age-specific or local reference ranges, should have prostate cancer excluded to the Investigator's satisfaction in conjunction with shared decision making [SDM] with the study subjects). Confirmed or suspected bladder cancer. History of cystolithiasis, kidney stone, or kidney disease within the prior 3 months. History of neurogenic bladder. Previous episode of AUR, i.e., post hernia repair or other condition or disease that might cause urinary retention.

 
Keywords and/or Specific Medical Conditions
  • Surgery (General)
  • Urology
  • Surgery (Urology)
 
KP Clinical Facility
  • Santa Clara Medical Center -Campbell
  • Santa Clara Medical Center -Milpitas
  • Santa Clara Medical Center-Homestead
  • Santa Clara Medical Center-Mountain View
 
Clinical Area
  • Surgery (General)
  • Surgery (Urology)
  • Urology


Principal Investigator:
Sarah Chan, MD
Contact Information:
- CTP Team
-CTPCollaborate@kp.org
-All Kaiser Permanente Northern California Medical Centers


smilelady1
Do you want to receive
Email Alerts?

Sign Up Here!





Regional Research Sites: